How prolonged delivery of a nanoparticle vaccine affects antibody responses in infants
Official title: Regulation of the HA stem nanoparticle vaccine response by antigen duration
Funded at Wake Forest University Health Sciences · NIH-11114955 · Data updated 2026-11-12
This study is looking at how giving vaccines in a new way can help babies build stronger defenses against illnesses, so they might only need one shot instead of multiple doses.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | March 21, 2025 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $228,195 |
| NIH project number | 1R21AI190892-01 |
| Project ID | NIH-11114955 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are infants under 6 months of age who are at risk of poor vaccine responses.
✕Less likely to help
Patients who are older than 6 months or those with existing immune deficiencies may not benefit from this research.
What this research studies
This research investigates how the timing and method of vaccine delivery can enhance the immune response in infants, who typically struggle to produce adequate antibodies after vaccination. By using a nanoparticle vaccine that delivers antigens over an extended period, the study aims to determine if this approach can lead to stronger and more effective antibody production. The research focuses on understanding the unique immune characteristics of infants and how they can be leveraged to improve vaccine efficacy. If successful, this could lead to a new vaccination strategy that requires only a single dose for infants.
Why it matters
Potential benefit: If successful, this research could provide a more effective vaccination method for infants, potentially leading to better protection against infectious diseases.
How similar studies have gone: Other research has shown promise in enhancing vaccine responses through novel delivery methods, suggesting that this approach could be viable.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Alexander-Miller, Martha Ann — Wake Forest University Health Sciences
- Study coordinator: Alexander-Miller, Martha Ann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.